Gene delivery in the equine cornea: A novel therapeutic strategy

Veterinary Ophthalmology

Volumn 13, Issue 5, 2010, Pages 301-306

  Buss, Dylan G ^a,c   Giuliano, Elizabeth ^c   Sharma, Ajay ^a,b   Mohan, Rajiv R ^a,b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

Author keywords

AAV; Cornea; Equine; Fibroblasts; Fibrosis; Gene therapy

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN;

ADENO ASSOCIATED VIRUS; ANIMAL; ANIMAL DISEASE; ARTICLE; CORNEA; GENE THERAPY; GENE VECTOR; HORSE; METHODOLOGY; TISSUE CULTURE TECHNIQUE;

ANIMALS; CORNEA; DEPENDOVIRUS; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HORSES; TISSUE CULTURE TECHNIQUES;

ADENO-ASSOCIATED VIRUS; CYTOMEGALOVIRUS; EQUIDAE;

EID: 77956279674     PISSN: 14635216     EISSN: 14635224     Source Type: Journal    
DOI: 10.1111/j.1463-5224.2010.00813.x     Document Type: Article

References (32)

1. Mohan RR, Schultz GS, Hong JW. Gene transfer into rabbit keratocytes using AAV and lipid-mediated plasmid DNA vectors with a lamellar flap for stromal access. Experimental Eye Research 2003, 76:373-383.
2. Mohan RR, Sharma A, Netto MV. Gene therapy in the cornea. Progress in Retinal Eye Research 2005, 24:537-559.
3. Verma IM, Weitzman MD. Gene therapy: twenty-first century medicine. Annual Review of Biochemistry 2005, 74:711-738.
4. Monahan PE, Samulski RJ. Adeno-associated virus vectors for gene therapy: more pros than cons? Molecular Medicine Today 2000, 6:433-440.
5. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clinical Microbiology Review 2008, 21:583-593.
6. Michau TM, Schwabenton B, Davidson MG. Superficial, nonhealing corneal ulcers in horses: 23 cases (1989-2003). Veterinary Ophthalmology 2003, 6:291-297.
7. Brooks DE. Equine Ophthalmology in Veterinary Ophthalmology 2007, 4th edn, Blackwell Publishing, Ames, IA
8. Haber M, Cao Z, Panjwani N. Effects of growth factors (EGF, PDGF-BB and TGF-beta 1) on cultured equine epithelial cells and keratocytes: implications for wound healing. Veterinary Ophthalmology 2003, 6:211-217.
9. Nasisse MP, Nelms S. Equine ulcerative keratitis. Vet Clinics of North America Equine Practice 1992, 8:537-555.
10. Monahan PE, Samulski RJ. AAV vectors: is clinical success on the horizon? Gene Therapy 2000, 7:24-30.
11. Lebherz C, Maguire A, Tang W. Novel AAV serotypes for improved ocular gene transfer. The Journal of Gene Medicine 2008, 10:375-382.
12. Royo NC, Vandenberghe LH, Ma JY. Specific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicity. Brain Research 2008, 1190:15-22.
13. Saika S, Yamanaka O, Sumioka T. Fibrotic disorders in the eye: targets of gene therapy. Progress in Retinal Eye Research 2008, 27:177-196.
14. Alexander JJ, Hauswirth WW. Adeno-associated viral vectors and the retina. Advances in Experimental Medicine and Biology 2008, 613:121-128.
15. Surace EM, Auricchio A. Versatility of AAV vectors for retinal gene transfer. Vision Research 2008, 48:353-359.
16. Bainbridge JW, Smith AJ, Barker SS. Effect of gene therapy on visual function in Leber's congenital amaurosis. The New England Journal of Medicine 2008, 358:2231-2239.
17. Maguire AM, Simonelli F, Pierce EA. Safety and efficacy of gene transfer for Leber's congenital amaurosis. The New England Journal of Medicine 2008, 358:2240-2248.
18. Auricchio A, Rolling F. Adeno-associated viral vectors for retinal gene transfer and treatment of retinal diseases. Current Gene Therapy 2005, 5:339-348.
19. Surace EM, Domenici L, Cortese K. Amelioration of both functional and morphological abnormalities in the retina of a mouse model of ocular albinism following AAV-mediated gene transfer. Molecular Therapy 2005, 12:652-658.
20. Chadderton N, Millington-Ward S, Palfi A. Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. Molecular Therapy 2009, 17:593-599.
21. Van Vliet KM, Blouin V, Brument N. The role of the adeno-associated virus capsid in gene transfer. Methods in Molecular Biology 2008, 437:51-91.
22. Sharma A, Ghosh A, Hansen ET. Transduction efficiency of AAV 6, 8 and 9 vectors for delivering genes in human corneal fibroblasts. Brain Research Bulletin 2010, 81:273-279.
23. Ghosh A, Yue Y, Duan D. Viral serotype and the transgene sequence influence overlapping adeno-associated viral (AAV) vector-mediated gene transfer in skeletal muscle. The Journal of Gene Medicine 2006, 8:298-305.
24. Limberis MP, Vandenberghe LH, Zhang L. Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Molecular Therapy 2009, 17:294-301.
25. Buss D, Giuliano E, Sharma A. Isolation and cultivation of equine corneal fibroblasts, keratocytes and myofibroblasts. Veterinary Ophthalmology 2010, 13:37-42.
26. Louboutin JP, Wang L, Wilson JM. Gene transfer into skeletal muscle using novel AAV serotypes. The Journal of Gene Medicine 2005, 7:442-451.
27. Gao G, Lu Y, Calcedo R. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Molecular Therapy 2006, 13:77-87.
28. Netto MV, Mohan RR, Sinha S. Effect of prophylactic and therapeutic mitomycin C on corneal apoptosis, cellular proliferation, haze, and long-term keratocyte density in rabbits. Journal of Refractive Surgery 2006, 22:562-574.
29. Mohan RR, Gupta R, Sinha S. Decorin transfection suppresses expression of profibrogenic genes and inhibits myofibroblast formation in human corneal fibroblasts. Exp Eye Res 2010, 10.1016/j.exer.2010.05.013, doi
30. Maltseva O, Folger P, Zekaria D. Fibroblast growth factor reversal of the corneal myofibroblast phenotype. Investigative Ophthalmology and Vision Science 2001, 42:2490-2495.
31. Morrison DF, Foss DL, Murtaugh MP. Interleukin-10 gene therapy-mediated amelioration of bacterial pneumonia. Infection and Immunolgy 2000, 68:4752-4758.
32. Sharma A, Ghosh A, Siddappa C. Ocular surface: gene therapy. Encyclopedia of the Eye 2010, 2:185-194.